-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It is predicted that by 2025, there will be 380 million people with type 2 diabetes worldwide, of which 17.
Diabetic Vascular Cholesterol Prevention Researchers have compared the effects of different statins on non-high-density lipoprotein cholesterol (non-HDL-C) levels and cardiovascular disease risk in diabetic patients
Effects of different statins on non-HDL-C levels in people with diabetes and hyperlipidemia
Effects of different statins on non-HDL-C levels in diabetic patients with hyperlipidemiaStudies have shown that for people with diabetes and hyperlipidemia, medium and high doses of rosuvastatin and high doses of simvastatin and atorvastatin can effectively reduce non-high-density lipoprotein cholesterol levels
For people with diabetes and hyperlipidemia, medium and high doses of rosuvastatin and high doses of simvastatin and atorvastatin can effectively reduce non-high-density lipoprotein cholesterol levels
.
For people with diabetes and hyperlipidemia, medium and high doses of rosuvastatin and high doses of simvastatin and atorvastatin can effectively reduce non-high-density lipoprotein cholesterol levels
.
Original source:
Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.
Leave a comment here